On April 20, 2026, Celldex Therapeutics, Inc. (CLDX) received an upgrade to an “Overweight” rating from Barclays analyst Etzer Darout, suggesting a notable upside potential for the stock. With a current price of $34.55 and a target price of $45, this upgrade signals to investors that Celldex may present an attractive investment opportunity, particularly in the context of its recent performance and broader market dynamics.
Recent Price Action
Celldex’s stock has demonstrated a fluctuating trajectory in recent trading sessions, reflecting a mix of investor sentiment and market volatility. Currently priced at $34.55, the stock has experienced a slight uptick of 0.04, or approximately 0.11%. However, the company’s performance is juxtaposed against a 52-week high of $112.78 and a low of $40.01, indicating a significant decline from its peak. The stock’s beta of 1.196 suggests higher volatility compared to the broader market, contributing to the recent trading behavior characterized by a notable daily volume of approximately 370,365 shares, which is below its average volume of around 995,863.
[chart type=’price’ value=’CLDX’]
Short- and Long-Term Performance
Over the last 30 days, Celldex has exhibited a decline of 2.44%, reflecting short-term headwinds. This decline is compounded by a quarterly performance drop of 6.3%. Yet, the stock has shown resilience on a yearly basis, boasting a 10.46% increase amidst broader market fluctuations. Notably, the average volume over the last three months stood at approximately 997,106, while the recent weekly volatility hovered at 3.87%. The contrast in performance between the short-and long-term highlights potential recovery opportunities, providing insights for investors considering different time horizons.
[chart type=’performance’ value=’CLDX’]
Earnings Analysis
In the latest earnings report, released on November 10, 2025, Celldex reported an actual earnings per share (EPS) of -$1.01, falling short of the estimated -$0.88. This 14.77% negative surprise raises red flags regarding the company’s earnings quality and predictability, particularly when compared to the preceding quarter, where the actual EPS of -$0.85 was roughly in line with the estimate of -$0.86. The widening discrepancy in this quarter suggests challenges in achieving profitability, which may affect investor confidence moving forward.
[chart type=’income-bar-chart’ value=’CLDX’]
Analyst / Consensus View
Overall, sentiment surrounding Celldex remains cautiously optimistic. The stock currently holds a total of three ratings from analysts, with two classified as “Buy” and one as “Hold,” while there haven’t been any “Sell” ratings assigned. The average price target stands at $49, with a high target reaching up to $68 and a low target of $34. This range indicates a spectrum of confidence among analysts regarding Celldex’s potential, underscored by Barclays’ recent upgrade, which aligns with the belief in the company’s capacity for future growth.
[chart type=’analyst-ratings’ value=’CLDX’]
Stock Grading or Fundamental View
Celldex Therapeutics, Inc. holds a Stocks Telegraph Grade (ST Score) of 43, which summarizes the company’s overall investment profile based on comprehensive financial and market analysis. While this score suggests that the company faces challenges, it also implies a foundation upon which it could potentially build as it navigates through its current market phase. Investors should consider the implications of this score in relation to their investment strategies.
[chart type=’st-cards’ value=’CLDX’]
Conclusion
For investors contemplating exposure to Celldex Therapeutics, the stock may prove suitable for those with a higher risk tolerance, particularly those seeking long-term growth opportunities in the biotechnology sector. The recent upgrade to “Overweight” by Barclays, alongside the identified upside potential, presents a compelling narrative for interested investors. Nevertheless, the risks associated with its recent earnings performance and persistent volatility must be weighed carefully. Celldex’s journey will warrant close observation as it endeavors to enhance its financial predictability and performance in the months ahead.